Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | FGF23 | Q9GZV9 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27198359 | 0.80 | KMT2A (0.64) | ALDH1A1KDM4EGAAKMT2AACHE | |
| SCHEMBL5668373 | 0.80 | KMT2A (0.64) | ALDH1A1KDM4EGAAKMT2AACHE | |
| SCHEMBL6319705 | 0.80 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL4275687 | 0.80 | KMT2A (0.64) | ALDH1A1KDM4EGAAKMT2AACHE | |
| SCHEMBL4275683 | 0.80 | KMT2A (0.64) | ALDH1A1KDM4EGAAKMT2AACHE | |
| SCHEMBL2205548 | 0.77 | GRIN2D (0.58) | ALDH1A1KDM4EGAAKMT2AACHE | |
| SCHEMBL2205545 | 0.77 | GRIN2D (0.58) | ALDH1A1KDM4EGAAKMT2AACHE | |
| SCHEMBL2556380 | 0.74 | ALDH1A1 (0.41) | ALDH1A1KDM4EGAAKMT2AMEN1 | |
| SCHEMBL2553134 | 0.74 | ALDH1A1 (0.40) | ALDH1A1KDM4EGAAKMT2AACHE | |
| SCHEMBL2161965 | 0.73 | NPC1 (0.64) | ALDH1A1KDM4EGAAKMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3878851-A1 | PROCESS FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2021-09-15 | — | — | EP | disclosed |
| US-10822331-B2 | Processes for preparing ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3608316-A1 | DEUTERATED DERIVATIVES OF AN INHIBITOR OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10435397-B2 | — | — | 2019-10-08 | — | — | US | disclosed |
| EP-2940017-B1 | Process for making compounds useful as inhibitors of ATR kinase | VERTEX PHARMA (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190202818-A1 | PROCESSES FOR PREPARING ATR INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2019-07-04 | — | — | US | disclosed |
| US-10208027-B2 | Processes for preparing ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180244662-A1 | PROCESSES FOR PREPARING ATR INHIBITORS | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2018-08-30 | — | — | US | disclosed |
| EP-2940017-A2 | PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2751097-A2 | PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013049726-A2 | PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822331-B2 | Processes for preparing ATR inhibitors | ATR, ATRIP, CHEK1 | ALDH1A1 3365/4885KDM4E 1434/4885GAA 1919/4885 |
| US-20190202818-A1 | PROCESSES FOR PREPARING ATR INHIBITORS | ATR, ATRIP, CHEK1 | ALDH1A1 3323/4885KDM4E 1363/4885GAA 1997/4885 |
| US-10435397-B2 | — | ATR, ATRIP, TBK1 | ALDH1A1 2981/4885KDM4E 1636/4885GAA 1633/4885 |
| US-20180244662-A1 | PROCESSES FOR PREPARING ATR INHIBITORS | ATR, ATRIP, CHEK1 | ALDH1A1 3323/4885KDM4E 1363/4885GAA 1997/4885 |
| US-10208027-B2 | Processes for preparing ATR inhibitors | ATR, ATRIP, CHEK1 | ALDH1A1 3323/4885KDM4E 1363/4885GAA 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.